🇺🇸 FDA
Patent

US 10392386

JAK inhibitors containing a 4-membered heterocyclic amide

granted A61KA61K31/437A61P

Quick answer

US patent 10392386 (JAK inhibitors containing a 4-membered heterocyclic amide) held by Theravance Biopharma R&D IP, LLC expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance Biopharma R&D IP, LLC
Grant date
Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K31/437, A61P, A61P11/00, A61P11/06